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Objective: Reduced myocardial performance invariably follows pediatric cardiac surgery and is manifested by
a low cardiac output state in its severest form. The role of myocardial membrane proteins in this setting is un-
known. Dystrophin and dysferlin are involved in membrane integrity, whereas aquaporins selectively transport
water. These proteins were examined in a model of pediatric cardiac surgery, together with a trial of poloxamer
188, which may reduce membrane injury.
Methods: Eight lambs were randomized to saline with or without poloxamer 188. Lambs underwent 2 hours of
cardiopulmonary bypass and aortic crossclamping. After a further 9 hours of monitoring, the hearts were assessed
for water content, capillary leak, and protein expression.
Results: Dystrophin expression was unaffected by ischemia/reperfusion, but dysferlin expression was reduced.
Aquaporin 1 protein increased after ischemia/reperfusion. Poloxamer 188 administration was associated with
supranormal levels of dystrophin, preservation of dysferlin expression, and normalization of aquaporin 1 expres-
sion. Poloxamer 188 was associated with less capillary leak, maintained colloid osmotic pressure, and less hemo-
dilution. Poloxamer 188 was associated with an improved hemodynamic profile (higher blood pressure, higher
venous saturation, and lower lactate), although the heart rate tended to be higher.
Conclusions: Changes in protein expression within the myocardial membrane were found in a clinically relevant
model of pediatric cardiac surgery. Indicators of reduced performance, such as lower blood pressure and lower
oxygen delivery, were lessened in association with the administration of the membrane protecting poloxamer
188. Poloxamer 188 was also associated with potentially beneficial changes in membrane protein expression,
reduced capillary leakage, and less hemodilution.
Congenital Heart Disease Egan et alReduced myocardial performance may complicate repair of
congenital cardiac disease. It occurs to varying degrees, with
the most severe form being the low cardiac output state
(LCOS). It manifests with reduced perfusion and oxygen
delivery—tachycardia, systemic hypotension, oliguria, and
cool peripheries. Up to 25% of patients have a moderate
to severe form necessitating optimization of inodilation or
institution of mechanical support. Onset usually occurs 6
to 12 hours postoperatively, and it causes the majority of
morbidity and mortality in the current era. Although the im-
pact of LCOS is lessened by early supportive measures, such
as milrinone, its precise etiology remains somewhat elu-
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doi:10.1016/j.jtcvs.2008.10.0091154 The Journal of Thoracic and Cardiovascular Susive.1 A myriad of intraoperative events contribute. There
is direct operative myocardial trauma, a systemic inflamma-
tory response to the artificial surfaces of the extracorporeal
cardiopulmonary bypass (CPB) circuit, and ischemia/reper-
fusion (I/R) injury. Myocardial stunning, hypocontractility
despite normal perfusion, results from I/R injury and in-
volves a degree of myocardial edema and capillary leak
within the heart,2 but edema and dysfunction may not be
causally associated.3 Hemodilution, however, has been as-
sociated with LCOS, with reduced myocardial oxygen deliv-
ery and an early increase in lactate after CPB.4 Contractile
failure has also been demonstrated,5 together with apopto-
sis6 and a loss of key contractile elements.2 The effect of
I/R on membrane proteins that surround the contractile pro-
teins are essentially unknown in the clinical situation. Mem-
brane proteins are fundamentally involved in maintenance of
normal cellular structure and function, and proteins such as
dystrophin and dysferlin have been shown to play key roles
in mechanotransduction7 and membrane repair in other set-
tings.8 Aquaporins (AQPs), present in endothelial cells and
the sarcolemma of cardiomyocytes,9 are fundamental to wa-
ter handling and involved in development and resolution of
edema in other organs.10 Potentially, these membrane pro-
teins may be affected by CPB and I/R and have a role in
the pathophysiology of LCOS.rgery c May 2009





CPB ¼ cardiopulmonary bypass
I/R ¼ ischemia/reperfusion
LCOS ¼ low cardiac output state
P188 ¼ poloxamer 188
PBS ¼ phosphate-buffered saline
Dystrophin is a large protein intrinsic to the integrity of the
myocardial cellular structure, linking intracellular and extra-
cellular components. The structural role of dystrophin in car-
diac muscle is to stabilize the cell membrane while relating
the extracellular matrix to the contractile apparatus. The loss
of dystrophin from the membrane component of myocar-
dium has been associated with dysfunction. Loss of dystro-
phin can lead to loss of contractile strength and impaired
membrane integrity, leading to cell death.11
Dystrophinopathy or impaired dystrophin function has not
been investigated in the post-CPBsetting.Adystrophinopathy
has been described in a number of settings somewhat analo-
gous to the postoperative LCOS settings, albeit more severe,
such as end-stage ischemic cardiomyopathy,12 Coxsackie B
myocarditis,13 and animal models of coronary occlusion.14,15
Potential analogies between LCOS and an ischemia-induced
dystrophinopathy are supported by protection against loss of
dystrophin and maintenance of function with ischemic pre-
conditioning.14We exploredwhether dystrophinwas affected
in an animalmodel of LCOS.We further investigatedwhether
poloxamer 188 (P188) therapy, found to rapidly ameliorate
cardiac dysfunction in a mouse model of abnormal dystro-
phin,16 may be beneficial in this setting.
P188 is a nonionic surfactant with a plethora of purported
properties and actions when administered. Its main proposed
effects fall into two groups. First, hemorheologic effects—it
has been used to improve viscosity, reduce intravascular co-
agulation, and improve small vessel blood flow in the setting
of coronary artery surgery and sickle cell anemia.17,18 He-
modilution in the setting of pediatric cardiac surgery has
been shown to be associated with worsening of cardiac per-
formance, and it has been postulated that reduced hemo-
dilution optimized microcirculatory flows and improved
outcomes after surgery.4 Given the potential hemorheologic
effects of P188, we explored whether it affected the occur-
rence of hemodilution in this setting. The second group of
properties of P188 are its membrane repair effects—it has
been used in models of electrocution, myocardial ischemia,
and myocardial membrane fragility.16,19,20 We considered
that it was a reasonable therapy given its myriad of potential
beneficial effects in the setting of CPB and its safety profile
in human studies.17,18,20
Dysferlin, another important membrane-associated pro-
tein within the myocardium, has largely been overlooked.The Journal of Thoracic and CIt has been shown to be critical to membrane integrity
through membrane repair, and its loss contributes to in-
creased cell permeability.21 The loss of both dystrophin
and dysferlin creates a membrane that is readily injured, as
shown with increased permeability to Evans blue dye.8
The role of dysferlin in the setting of CPB is unknown,
and we sought to investigate its response to CPB with I/R
and whether its expression altered with P188.
Concurrently, we furthered previous investigations into
the response of myocardial water channels, in particular
AQP1, in the setting of LCOS. We3 have previously shown
increased AQP1 transcript after 3 hours’ reperfusion and
sought to examine protein levels over a longer time frame.
MATERIALS AND METHODS
TheAnimalEthicsCommittee at TheChildren’sHospital atWestmead ap-
proved this study, and all animals received humane care in compliance with
National Health and Medical Research Council animal care guidelines.22
Study Design
Eight lambs of either sex weighing 20.3 1.7 kg were used. Three lambs
received placebo (CPBP188) and 5 received P188 (CPBþP188).
Lambs received a blinded solution (2 mL/kg) as a bolus load over 1 hour
before CPB and then an infusion (0.2 ml $ kg1 $ h1) of the same solution
for the remainder of the experiment, 11 hours. Administration was through
the central line via an opaque extension (Codan Medlon, Inc, Santa Ana,
Calif) and a dedicated syringe driver (Graseby 3200; Graseby Medical,
Watford, United Kingdom). The solution was prepared immediately
before the experiment. It was filtered via a 0.22-mmfilter unit (Millipore Co,
Cork, Ireland) and wrapped in foil. Phosphate-buffered saline (PBS) was
the carrier solution administered without P188 to placebo animals. In treat-
ment animals, P188, also called Pluronic F-68 (Sigma Chemical Co, St
Louis, Mo), was added to give a concentration of 150 mg/mL in PBS, as
per previous reports.17 Staff involved in animal experiments were unaware
of the animal allocation until all data had been analyzed.
In earlier experiments,3 3 lambs were anesthetized, received no
PBSP188, proceeded similarly to sternotomy, and were humanely killed
before CPB, for non-CPB data (non-CPB controls).
Experimental preparation. Lambs were anesthetized by sponta-
neously breathing isoflurane and given intravenous ketamine (1 mg/kg)
and midazolam (100 mg/kg). The lambs were intubated with a 5.5-mm
cuffed endotracheal tube. Ventilation and invasive monitoring techniques
were relatively standard and identical to that previously described.3 Ve-
nous and arterial blood gases were measured regularly. Baseline full
blood count, coagulation, liver function, urea, creatinine, and creatinine
kinase were measured before CPB. These tests were repeated 6 hours
after CPB.
CPB technique. Within an hour of intubation, midline sternotomy
was performed and the pericardium was opened. CPB was established after
heparin administration (400 IU/kg) with right atrial and ascending aorta can-
nulation. The extracorporeal circuit and prime used were relatively standard
and identical to those previously described.3 Cardioplegia was repeated ev-
ery 20 minutes for 120 minutes, at which point the animal was weaned from
CPB and native circulation was re-established. Modified ultrafiltration was
performed on all, and internal defibrillation (0.5–1.0 J/kg) and/or lidocaine
(1 mg/kg) administered as required.
Postoperative management. After the re-establishment of the
circulation, protamine (1–3 mg/kg) was given and hemostasis achieved.
The sternotomy was closed over two 28F intrathoracic drains, which were
placed on low-pressure wall suction. Dopamine (5 mg $ kg1 $ min1) andardiovascular Surgery c Volume 137, Number 5 1155
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Dsodium nitroprusside (1 mg $ kg1 $min1) were commenced after CPB and
kept at these rates. A mean blood pressure greater than 50 mm Hg was
sought, with crystalloid or maternal blood given to maintain an adequate
preload (central venous pressure) greater than 4 mm Hg and hemoglobin
(hemoglobin> 8 g/dL). Inhalational anesthesia was adjusted according
to blood pressure and was supplemented with intermittent intravenous
agents (ketamine and midazolam) and pancuronium. Ventilation was
maintained and adjusted according to blood gas parameters. All animals
were managed by a pediatric intensive care consultant (J.R.E.) using con-
ventional techniques relevant to the care of human infants. Seven hours
after completion of CPB, 0.2 mg/kg of 0.1% Evans blue dye was given
intravenously.23
Tissue collection. Nine hours after CPB, the sternotomy was reop-
ened and a dose of pentobarbitone was delivered. After electrical and
cardiac standstill, the heart was removed and placed on ice while being
dissected for further analysis. The heart was transversely sectioned into at-
ria, great vessels, and ventricles. The ventricles were sectioned for wet/dry
weights and together with other organ tissues were either frozen at80C or
placed in 4% paraformaldehyde for histologic processing.
TABLE 1. Various measurements before and after CPB
Mean (±SEM)
Before CPB After CPB
Total CK (40–240 IU) 9 h 223 (44) 2092 (1388)
9 hþP188 204 (67) 1781 (415)
P value .5 .5
Dopamine 9 h 5.2 (0.2)
(mg $ kg1 $ min1) 9 hþP188 4.8 (0.5)
P value .4
Sodium nitroprusside 9 h 1 (0)
(mg $ kg1 $ min1) 9 hþP188 1.1 (0.1)
P value 1
Input (crystalloid) (mL) 9 h 767 (145) 1080 (205)
9 hþP188 808 (105) 1052 (225)
P value 1 1
Input (colloid) (mL) 9 h 477 (46)
9 hþP188 554(57)
P value .4
Input (total) (mL) 9 h 1557 (197)
9 hþP188 1606 (211)
P value .9
Chest drain loss (mL) 9 h 667 (133)
9 hþP188 420 (68)
P value .13
Platelets 3 109/L 9 h 315 (46) 249 (24)
9 hþP188 382 (12) 255 (61)
P value .16 .45
APTT (23–34 s) 9 h 33.8 (5) 36.9 (6)
9 hþP188 35 (3) 40.2 (5)
P value .7 .5
Fibrinogen (1.5–6 g/L) 9 h 2.5 (0.5) 2.2 (0.3)
9 hþP188 2.3 (0.3) 2.3 (0.1)
P value .7 .5
Mean ACT (on CPB) 9 h 560 (80)
9 hþP188 622 (39)
P value .7
SEM, Standard error of the mean; CPB, cardiopulmonary bypass; CK, creatinine
kinase; APTT, activated partial thromboplastin time; ACT, activated clotting time;
P value, Mann–Whitney U test.1156 The Journal of Thoracic and Cardiovascular SuTissue Analysis
Myocardial water content. Samples of intraventricular septum
and left and right ventricular free walls were weighed after blotting. They
were dried at80C for 48 hours or until their weight was static. Myocardial
water content was calculated by ([Wt (wet)Wt (dry)]/[Wt (wet)]) and ex-
pressed as a proportion.24 Staining of the myocardium with Evans blue dye
was assessed (blinded to allocation) by reviewing five 1003 fields and
staining rated as abundant (2), present (1), or absent (0).
Myocardial AQPs. Protein forWestern analysis was prepared as pre-
viously described,25 using whole cell lysates from frozen tissue.Membranes
were blocked and then incubated with the following primary antibodies,
AQP1 (AQP11-A, 1:1000; Alpha Diagnostics, San Antonio, Tex), cardiac/
skeletal actin (5c5 1:3000; Sigma–Aldrich, St Louis, Mo). Total RNA was
extracted from tissues using Tri Reagent (Molecular Research Center, Cin-
cinnati, Ohio) followed by cDNA synthesis using random primers pd(N)6
(Roche, Mannheim, Germany) and reverse transcriptase (Superscript III; In-
vitrogen, Carlsbad, Calif). Quantitative reverse transcriptase–polymerase
chain reaction was performed with LUX primers (Invitrogen) as previously
described.3 All samples were run in duplicate and experiments performed in
triplicate. AQP levels were quantified during 45 cycles with a Rotor-Gene
RG 3000A (Corbett Research, Mortlake, NSW, Australia), and analysis
was performed with Rotor-Gene Real Time Analysis Version 6.0 (Corbett
Research, 2004). AQP mRNA levels were normalized to 18S rRNA.
Myocardial dystrophin and dysferlin. Total protein for West-
ern analysis was prepared as previously described.25 Membrane and myo-
cellular preparations were prepared according to the published method of
Kido and associates14 after ultracentrifugation and then run as previously
described.25 Membranes were probed with the following primary antibodies
for dystrophin: MANDRA-1 (1:250) (Sigma-Aldrich) for the C terminus,
Dys1 (1:200) (Novocastra, Newcastle, United Kingdom) for the rod do-
main, and Dys3 (1:20) (Novocastra) for the N-terminus, with appropriate
positive and negative controls.12,14,15 Dysferlin was detected with the anti-
body Hamlet1 (1:200) (Novocastra). Loading was controlled with an anti-
body to a-actinin-2 (1:200,000).
Statistical Analysis
Data were expressed as means SEM. Statistical significance was deter-
mined by both the Mann–WhitneyU test and linear mixed models using co-
variance type AR-1. The statistical package SPSS version 15.0 for Windows
(SPSS, Inc, Chicago, Ill) was used for analysis. The animals with or without
P188 were compared in terms of hemodynamic variables—both functional
and biochemical. Hemodynamic data variables were analyzed over the com-
plete survival period and also by comparison of 60-minute epochs. Our sam-
ple size gave us 80% power to demonstrate that a 0.7 standard deviation effect
size difference between groups was significant at a P value of 0.05.26 For
measures of protein expression, myocardial water, and blood tests, com-
parison was made between control animals and 9-hour post-CPBP188.
RESULTS
All experiments were completed as intended. No ino-
tropes or vasodilators were administered before CPB, and
rates of administration after CPB were similar (Table 1).
There were no significant differences in pre-CPB hemody-
namic values, apart from a lower heart rate in the CPBþP188
group (Table 2).
Molecular Results
Dystrophin, measured in membrane fractions, was un-
changed in the CPBP188 group compared with non-CPB
controls (P ¼ .3). Membrane dystrophin expression wasrgery c May 2009
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DTABLE 2. Hemodynamic and laboratory variables post-CPB
Hours after CPB
Baseline 1 2 3 4 5 6 7 8 9
Mean (SEM)
CVP (mm Hg)
9 h 2.0 (0.5) 3.3 (0.6) 2.6 (0.4) 2.9 (0.4) 3.1 (0.4) 2.6 (0.4) 1.9 (0.4) 2.5 (0.6) 2.6 (0.5) 2.7 (0.6)
9 h +P188 2.5 (0.5) 4.2 (0.6) 3.5 (0.5) 2.8 (0.4) 2.7 (0.4) 2.7 (0.4) 2.8 (0.4) 2.7 (0.4) 2.1 (0.5) 2.3 (0.4)
P value* .5 .37 .52 .17 .14 .49 .91 .51 .66 .75
P valuey .88
HR (beats/min)
9 h 131 (6) 148 (4) 153 (3) 152 (5) 147 (3) 157 (5) 156 (4) 145 (3) 135 (3) 127 (2)
9 h +P188 107 (4) 147 (3) 153 (3) 162 (3) 163 (2) 158 (2) 159 (3) 161 (2) 155 (3) 144 (3)
P value* <.01 .75 .62 .2 <.01 .54 .64 <.01 <.01 <.01
P valuey .15
SBP (mm Hg)
9 h 93 (5) 94 (3) 93 (3) 101 (3) 101 (2) 91 (2) 84 (1) 79 (2) 74 (2) 75 (2)
9 h +P188 89 (3) 96 (3) 102 (2) 102 (1) 95 (1) 91 (2) 95 (2) 93 (2) 87 (2) 84 (2)
P value* .6 .47 .01 .54 .02 .99 <.01 <.01 <.01 <.01
P valuey .12
MBP (mm Hg)
9 h 75 (4) 66 (4) 72 (3) 76 (2) 75 (2) 69 (2) 62 (1) 58 (2) 55 (1) 56 (2)
9 h +P188 74 (3) 76 (3) 84 (2) 81 (1) 75 (1) 73 (2) 75 (2) 73 (1) 68 (2) 65 (1)
P value* .8 .04 <.01 .05 .97 .08 <.01 <.01 <.01 <.01
P valuey <.01
DBP (mm Hg)
9 h 62 (3) 60 (3) 55 (3) 58 (2) 57 (2) 51 (1) 46 (1) 43 (2) 41 (1) 43 (2)
9 h +P188 62 (3) 63 (3) 70 (1) 63 (1) 56 (1) 56 (2) 58 (1) 54 (1) 51 (1) 49 (1)
P value* .8 .43 <.01 .02 .78 .03 <.01 <.01 <.01 <.01
P valuey <.01
COP (mOsm) D from baseline
9 h 13.3 (0.8) 2 (0.3) 1.2 (0.2) 1.8 (0.5) 3.5 (0.5)
9 h +P188 12.6 (0.5) 0.4 (1.8) 0.5 (0.8) 1.4 (1.4) 1.5 (0.6)
P value* .30 .46 .37 .55 .02
Hct (%) D from baseline
9 h 29.4 (2.1) 3.9 (2.9) 5.0 (1.8) 3.2 (1.2) 2.9 (2.1)
9 h +P188 23.8 (1.8) 7.1 (2.3) 5.8 (1.4) 7.7 (1.7) 5.6 (3.0)
P value* .1 .05 .03 .03 .1
Hb (g/dL) D from baseline
9 h 9.5 (0.7) 1.3 (0.9) 1.7 (0.6) 1.1 (0.4) 1.0 (0.7)
9 h +P188 8.0 (0.6) 2.0 (0.8) 1.6 (0.4) 2.2 (0.5) 2.1 (0.7)
P value* .18 .05 .03 .03 .05
Venous sat (%) D from baseline
9 h 92.5 8.5 (6.3) 0.5 (3.4) 6.7 (1.5) 9.4 (2.5)
9 h +P188 82.8 3.8 (14.3) 13.3 (7.3) 8.6 (7.1) 9.6 (7)
P value* .65 .72 .30 .05 .05
Lactate (mmol/L) D from baseline
9 h 1.23 (0.26) 3.83 (0.72) 0.83 (0.28) 0.10 (0.2) 0.23 (0.2)
9 h +P188 2.14 (0.42) 1.26 (0.67) 0.56 (0.5) 1.08 (0.4) 1.18 (0.4)
P value* .10 .04 .07 .17 .09
CPB,Cardiopulmonary bypass;CVP, central venous pressure;HR, heart rate; SBP, systolic blood pressure;MBP,mean blood pressure;DBP, diastolic blood pressure;COP, colloid
osmotic pressure; Hct, hematocrit; Hb, hemaglobin. *P value calculated by Mann–Whitney U test. yP value calculated after CPB by linear mixed models using covariance type
AR-1.higher in the CPBþP188 group (using antibodies to both C-
terminus and rod domain) compared with CPBP188 and
non-CPB control groups (P< .05, Figure 1, A). Antibodies
to the N-terminus of the human form of dystrophin did not
cross-react with sheep dystrophin.The Journal of Thoracic and CDysferlin expressionwas significantly reduced at themem-
brane after CPB in the CPBP188 group compared with non-
CPB controls (P< .05). In the CPBþP188 group, there was
maintenance of dysferlin expression at levels similar to those
in the non-CPB control animals (P ¼ .8, Figure 1, B).ardiovascular Surgery c Volume 137, Number 5 1157
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DAQP1 protein levels were increased 9 hours after CPB
in the CPBP188 group compared with non-CPB controls
(P< .05). The CPBþP188 animals displayed less of a rise
in AQP1 protein expression than did non-CPB controls
(P ¼ .28, Figure 2).
Myocardial Water
Themyocardium of CPBP188 animals tended to be more
edematous (0.78  0.005) than the hearts of the CPBþP188
group (0.77  0.003), although nonsignificantly (P ¼ .08).
Evans blue dye uptake was greater in the CPBP188 group
(2.6 0.2) than in the CPBþP188 group (1.7 0.2; P<.05).
Albumin tended to fall by more in the CPBP188 animals
than the CPBþP188 group (3.33  0.67 g/L vs 0.8 
1.7 g/L), although nonsignificantly (P ¼ .17). Colloid
osmotic pressure was significantly reduced by 3.5  0.46
mOsm in the CPBP188 animals at 9 hours compared
with 1.46  0.58 mm Hg in the CPBþP188 animals
FIGURE 1. Myocardial membrane fraction densitometry. Membrane frac-
tions were measured by Western blot densitometry (controlled for protein
loading by a actinin-2 measurement). Lambs are grouped as non CPB-con-
trols (solid bar), CPBP188 (gray bar), and CPBþP188 (open bar). Protein
levels were compared between groups with the Mann–Whitney U test. A,
The CPBþP188 group shows higher membrane dystrophin levels than the
non-CPB control (*P<.05) and CPBP188 (#P< .05), B. The CPBP188
group shows a significant decrease in dysferlin expression compared with
the non-CPB control (*P< .05). CPB, Cardiopulmonary bypass.1158 The Journal of Thoracic and Cardiovascular Su(P< .05) (Figure 3 and Table 2). There were no significant
differences in volumes of crystalloid or colloid fluid admin-
istered (Table 1). There was a trend toward greater chest
drain losses in the CPBP188 group (P ¼ .13, Table 1).
Biochemistry and Hematology
Creatinine increased in the CPBP188 group by 10.7
 4.4 mmol/L, compared with a reduction in the CPBþP188
animals of 11  6.9 mmol/L (P< .05). Urea tended to in-
crease not significantly in the CPBP188 group 1.78 
0.49 mmol/L, whereas in the CPBþP188 animals it rose
by 0.72  0.67 mmol/L (P ¼ .18). Total creatinine kinase
did not differ significantly between groups (Table 1). The
CPBP188 group initially had a higher lactate after reperfu-
sion than did the CPBþP188 animals (P< .05, Figure 4, E,
and Table 2). Venous saturation was increased from base-
line in those receiving P188 at 6 and 9 hours after CPB
(P ¼ .05, Figure 4, F, and Table 2). P188 was associated
with a maintenance of hemoglobin and hematocrit com-
pared with baseline (Figure 3 and Table 2). There were no
significant differences in other hematology and coagulation
tests (Table 1).
Hemodynamics
Heart rate and systolic blood pressure tended to be lower
in the CPBP188 animals in the later epochs (P<.01 at 7–9
hours after CPB) but overall were not different (P¼ .15 and
P ¼ .12, respectively) (Figure 4, A and B, and Table 2). The
CPBP188 animals had significantly lower mean blood
pressure and diastolic blood pressure throughout the 9-
hour period after CPB (P< .01) (Figure 4, C and D, and
Table 2). Central venous pressure was similar overall be-
tween groups (P ¼ .88, Table 2).
FIGURE 2. Myocardial aquaporin 1 (AQP1) protein expression. Western
analysis of total AQP1 protein was normalized to cardiac actin. Lambs are
grouped as non-CPB controls (solid bar), CPBP188 (gray bar), and
CPBþP188 (open bar). Protein levels were compared between groups
with the Mann–WhitneyU test. Representative results demonstrate a signif-
icant increase at 9 hours after CPB in the CPBP188 group compared with
non-CPB controls (*P< .05). CPB, Cardiopulmonary bypass.rgery c May 2009




A clinically accurate animal model of reduced myocardial
performance was studied. Previously undescribed changes
in altered expression of proteins within the myocardial mem-
brane were found. Hallmarks of reduced performance, such
as lower blood pressure and lower oxygen delivery, were
lessened in association with the administration of the mem-
brane protecting P188. P188 treatment was also associated
with potentially beneficial changes in membrane protein ex-
pression, reduced capillary leakage, and reduced hemodilu-
tion. However, this was a small study and consequently its
findings can at best suggest avenues for further analysis.
Our use of clinically relevant surgical, perfusion, and anes-
thetic techniques provided a clinically valid model of the
milder spectrum of LCOS.
Dystrophin is a candidate protein in the contractile failure
that occurs in the setting of LCOS and has not been previ-
ously investigated in that context. Regional ischemia brought
about by coronary occlusion in animals has been shown to re-
duce both its membrane location and overall expression.14,15
Ischemic cardiomyopathy has also been associated with re-
duced dystrophin expression, but examinationwith a specific
N-terminus antibody was necessary.12 In several ways, re-
gional ischemia and end-stage ventricular failure represent
more severe forms of disease than that experiencedwith pres-
ent-day infant heart surgery. In our clinical model of LCOS,
we found no change in dystrophin after CPB with I/R. Evi-
dence from others suggests it is possible that changes oc-
curred only at the N-terminus, which we were not able to
study with the antibodies available for sheep. However, we
consider this unlikely, given that we observed increases in
dystrophin expression associated with P188 therapy that
were identical with both the rod domain and C-terminus an-
tibodies. CPBwith I/R represent a planned insult, and current
myocardial protection techniques appear adequate in pre-
venting an acute dystrophinopathy occurring in this setting.
Dysferlin has been shown to have a specific and critical
role in membrane injury in animal models of both skeletal
and cardiac muscle,8,21 but its response to CPB and I/R
has not previously been determined. Membrane dysferlin
protein expression was significantly reduced after CPB
and I/R in our study. Dysferlin loss was associated with ev-
idence of increased membrane damage and a greater reduc-
tion in colloid osmotic pressure. Available studies suggest
dysferlin-mediated membrane repair is indispensable for
the maintenance of cellular integrity in models of muscle
stress.8 Thus, the reduction in dysferlin associated with
CPB and I/R may represent an important aspect of the path-
ophysiology contributing to LCOS.
LCOS in this study was mild and characterized by lower
blood pressure and impaired oxygen delivery. Lactate was
raised after CPB whereas venous saturations and blood pres-
sure were reduced after CPB in the control group. Post-CPB
venous saturations, blood pressure, and lactate were im-The Journal of Thoracic and Caproved in association with P188. Hemoglobin was preserved
after CPB in associationwith P188 administration, and this is
likely to have partly contributed to improved oxygen deliv-
ery and hemodynamics in this group. Large studies have
shown an association between reduced hemodilution and im-
proved outcome. Interestingly, Jonas and colleagues4 in the
Boston Hemodilution Study also reported an initially raised
lactate after CPB in themore hemodiluted group. The control
animals in our study had a drop in hemoglobin on CPB, and
after CPB they were more hemodiluted than the CPBþP188
animals. These control animals also had an initially raised
lactate after CPB. This pattern of hemodilution was also
seen in our previous animal experiments.3 In the P188 group
of animals, however, there was a stable hemoglobin on CPB
and the lactatewas not as elevated as in the control group after
CPB. This rise in hemoglobinwasmaintained throughout the
postoperative period. Given that there were no substantive
differences in coagulation, the P188 may be responsible for
minimizing red cell loss and minimizing hemodilution
through reducing membrane injury.
FIGURE 3. Measures of colloid osmotic pressure and hemoglobin. Lambs
are grouped as CPBP188 (dashed line) and CPBþP188 (solid line). Com-
parison between groups was by the Mann–Whitney U test. A, Reduction in
colloid osmotic pressure was greater at 9 hours in the CPB–P188 group 3.5
 0.46 mm Hg compared with a drop of 1.46  0.58 mm Hg in the
CPBþP188 animals (*P< .05). B, Hemoglobin dropped in the CPBP188
group after CPB compared with the CPBþP188 animals (*P< .05). CPB,
Cardiopulmonary bypass; COP, colloid osmotic pressure; Hb, hemoglobin;
MUF, modified ultrafiltration.rdiovascular Surgery c Volume 137, Number 5 1159
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DFIGURE 4. Hemodynamic and biochemical variables. Lambs are grouped as CPBP188 (dashed line) and CPBþP188 (solid line). Comparison between
groups was by both the Mann–Whitney U test and linear mixed models using covariance type AR1 as appropriate. A, Heart rate (HR) was higher in the
CPBþP188 group during the later epochs, but overall the difference was not significant. B, Systolic blood pressure (SBP) was significantly higher in the
CPBþP188 group during the later epochs, but overall not different, C and D, Mean blood pressure (MBP) and diastolic blood pressure (DBP), respectively.
Both are significantly higher overall in the CPBþP188 group (*P< .01). E, Lower lactate in the CPBþP188 group after reperfusion (*P< .05), but similar
levels subsequently. F, The change in venous saturation after CPB compared with baseline was significantly higher in the CPBþP188 group at 6 and 9 hours
after CPB, with a final increase of 10%  7% compared with a drop in the CPBP188 group of 9%  3% (*P ¼ .05).Animals in the control group had unaltered dystrophin, re-
duced dysferlin expression, and increased membrane dam-
age. P188 has been shown by others to rapidly correct
abnormalities in dystrophin,16 although in the post–cardiac
surgery setting an acute dystrophinopathy was not apparent
in our study. Interestingly, P188 therapy was associated with
an increase in membrane dystrophin to supranormal levels.
Increased membrane dystrophin has been shown to occur
in response to ischemic preconditioning in an animal model,
suggesting that increased expression of dystrophin may have1160 The Journal of Thoracic and Cardiovascular Subeneficial functional effects.14 The role of this increase in
dystrophin expression cannot at this stage be linked to the
apparent improvements seen with this treatment.
It has been suggested that P188 would also be beneficial
in the setting of abnormalities in dystrophin-related proteins
such as dysferlin.16 P188 administration before CPB and I/R
was associated with maintenance of normal dysferlin levels.
Maintenance of dysferlin levels has been shown in other set-
tings to be associated with less membrane injury.8 There was
evidence of less membrane injury in the animals receivingrgery c May 2009
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DP188, and these animals also had higher levels of dysferlin
expression. Hence, dysferlin warrants further study in this
post-CPB setting.
P188 may have other hemodynamic effects. The prophy-
lactic use of P188 has shown benefit in improving blood
viscosity in a small trial of coronary bypass surgery.18 It
was also shown to have benefits on neurologic outcome after
deep hypothermic cardiac arrest in a large animal model of
CPB.27 Despite these benefits in planned ischemia, it was
not beneficial in a large trial as adjunctive therapy after acute
myocardial infarction.20 There were also no beneficial
effects on infarct size or hemodynamics, and safety concerns
arose with increased creatinine levels. It is possible that ben-
efits associated with P188 were obscured by patient hetero-
geneity and the failure of P188 to treat, rather than prevent,
ischemia-related injury. In our study, the use of modified ul-
trafiltration with CPB may have removed excess P188 and
perhaps minimized any renal injury. We did not demonstrate
a rise in creatinine associated with P188; in fact, creatinine
was reduced in those animals. We found a maintenance of
hemoglobin levels and no coagulopathy associated with its
use. P188 may also have reduced red blood cell fragility.
The role of edema and water transport proteins in the set-
ting of LCOS has not been established. We have previously
demonstrated that AQP1 mRNA increased 2-fold in the
setting of LCOS after CPB with I/R, but we did not observe
an associated rise in AQP1 protein at 3 hours.3 After a longer
period (9 hours) of observation, both AQP1 mRNA and
protein were increased 2-fold. While a 2-fold increase is
modest, the associated changes in capillary leak suggest
that AQP1 may have a role in capillary leak. The fact that
P188 was also associated with a normalization of raised
AQP1 protein levels and reduced markers of capillary leak
provides further support. To determine whether this change
in AQP1 expression is a pathologic or beneficial compensa-
tory response will require direct modulation of the channel.
Increased AQP1 expression could be part of the explanation
for the transudate that occurs into the tissues of the body
after CPB and I/R.28
This study was limited by its small size and by the fact that
it was conducted in animals. The animals also did not have
structural heart disease and hence no preoperative hypertro-
phy as a result of volume or pressure loading. A range of clin-
ically relevant refinements such as inotropes, vasodilators,
cardioplegia, and modified ultrafiltration were used to im-
prove the clinical validity of the model. These therapies are
likely to have reduced the underlying severity of LCOS
and may have had other effects, but because of their place
in current clinical practice, they were included. The hemody-
namic and functionalmonitoring used to support our findings
were simple, but equivalent and relevant to techniques relied
on in the clinical setting. All animals were managed in the
post-CPB period by one individual in the same way with
a view to maintaining critical parameters within acceptableThe Journal of Thoracic and Calimits. This best reflects clinical practice but added a poten-
tially confounding variable in assessing outcomes; blinding
to therapy should effectively have minimized any impact
from this variable. The molecular changes that occurred in
dysferlin and AQP proteins are novel and warrant further in-
vestigation. Load-independent measurements of systolic and
diastolic function would be beneficial in future studies to
completely define a functional benefit related to P188. Al-
though we have not sought to define the mechanistic action
of P188 in this study, we have generated data to support fur-
ther study of P188 in this setting.
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